Publications by authors named "R Hehlmann"

Claim this Profile
E
European LeukemiaNet criteria for safety and efficacy evaluation of new drugs for myelofibrosis.
Monia Marchetti, Alessandro Maria Vannucchi, John O Mascarenhas, Alberto Alvarez-Larran, Prithviraj Bose, Rűdiger Hehlmann

Blood Cancer J· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SOHO State of the Art Updates and Next Questions | Choosing the Best Frontline BCR::ABL1 Tyrosine Kinase Inhibitor in Chronic Myeloid Leukemia-How to Define the Treatment Value?
Fadi G Haddad, Elias Jabbour, Massimo Breccia, Rüdiger Hehlmann, Hemant Malhotra

Clin Lymphoma Myeloma Leuk· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Five-year molecular response and overall survival with first- and second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia in the chronic phase: a prospective, observational study - SIMPLICITY.
Michael J Mauro, Rüdiger Hehlmann, Loretta A Williams, Stuart L Goldberg, Mauricette Michallet

Leuk Lymphoma· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia.
Jane F Apperley, Dragana Milojkovic, Nicholas C P Cross, Henrik Hjorth-Hansen, Andreas Hochhaus, Rüdiger Hehlmann

Leukemia· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of chronic myeloid leukemia in 2025.
Hagop Kantarjian, Massimo Breccia, Fadi G Haddad, Rüdiger Hehlmann, Ghayas C Issa

Cancer· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis